Beyond the Scale: Retatrutide, Tesamorelin, and the Science of Body Composition

People who lift rarely mean only “a lower number” when they talk about a cut. They care about fat mass, lean tissue, gym performance, recovery, and how a physique looks. Drug trials do not always measure all of those outcomes, and treating them as interchangeable creates claims the evidence cannot support.

Retatrutide: three receptors, not “GLP-3”

Retatrutide is one peptide engineered to activate three established receptors: GIP, GLP-1, and glucagon receptors. GIP and GLP-1 participate in glucose and appetite signaling. Glucagon-receptor activity may add effects on energy expenditure and liver metabolism.

“GLP-3” or “GLP-3R” is informal commercial shorthand sometimes used for retatrutide. It is not a separate established hormone class, not the scientific name of retatrutide, and not proof that a product contains retatrutide. Researchers and the manufacturer call it a triple GIP/GLP-1/glucagon receptor agonist.

Human obesity evidence

In a peer-reviewed 2023 Phase 2 trial, 338 adults with obesity, or overweight plus a weight-related condition, and without diabetes were randomized to retatrutide or placebo for 48 weeks. Mean weight change ranged from 8.7% at the lowest dose to 24.2% at the highest dose, compared with 2.1% with placebo. Those are body-weight results in a defined clinical population, not a bodybuilding trial.

Gastrointestinal adverse events—especially nausea, diarrhea, vomiting, and constipation—were common and generally dose-related. Some participants discontinued treatment because of adverse events. Heart rate increased in a dose-dependent pattern and then declined after peaking. Benefits and discontinuations belong in the same account.

Evidence level — peer-reviewed human trial: substantial mean weight loss in adults meeting obesity-trial criteria. Not established: improved strength, muscle growth, a safer “cut,” or the same benefit-risk balance in lean lifters.

As of September 21, 2026, retatrutide remains investigational and is not FDA-approved. Lilly has announced positive Phase 3 topline findings. Those announcements are sponsor-reported until complete results undergo peer review. Trial registration and a manufacturer press release are not regulatory approval.

Weight loss is not one tissue

DXA substudies can divide body mass into fat and lean compartments. Retatrutide body-composition research in people with type 2 diabetes reported greater fat-mass loss than lean-mass loss. That ratio can be encouraging, but lean mass still declined. DXA “lean mass” includes water and organs as well as muscle, and it does not measure strength.

Resistance training, dietary intake, starting body composition, illness, measurement error, and the speed of weight loss all influence interpretation. A result in adults with obesity or diabetes does not automatically describe a lean athlete preparing for a competition.

Tesamorelin: a different pathway and a narrow indication

Tesamorelin is an analogue of growth-hormone-releasing hormone. It stimulates the pituitary to release growth hormone, which can raise insulin-like growth factor 1 (IGF-1). This is not the incretin pathway used by semaglutide, tirzepatide, or retatrutide.

Visceral fat lies around internal organs; subcutaneous fat lies beneath the skin. They are biologically and clinically different compartments. Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The current EGRIFTA SV label explicitly says it is not indicated for weight-loss management and is weight-neutral.

Clinical trials measured visceral adipose tissue in that specific population. They do not demonstrate that tesamorelin selectively removes the subcutaneous fat a lifter wants to lose, reveal abs from one area, or produces a bodybuilding benefit. “Reduced abdominal fat” in the labeled condition is not proof of cosmetic spot reduction.

Label risks matter

The current prescribing information warns about active malignancy, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, and risks in pregnancy. Fluid retention can present with swelling, joint discomfort, or nerve-compression symptoms. Because the pathway raises growth signaling, medical history and monitoring are integral to approved clinical use.

Evidence level — approved, population-specific human evidence: reduced visceral abdominal fat in adults with HIV-associated lipodystrophy. Not established: general weight management, targeted subcutaneous-fat loss, or improved gym performance.

Why the trial population matters

People entering obesity trials generally have a different starting risk-benefit calculation than lean lifters. A clinically meaningful reduction in weight and metabolic risk for one group does not answer whether a small additional reduction in body fat is worthwhile for another. Trials also provide protocol-driven follow-up and adverse-event monitoring that research-market products do not reproduce.

Physique goals further complicate interpretation. A scale can change with fat, glycogen, water, digestive contents, and lean tissue. DXA improves compartment estimates but has limits and still cannot tell whether a lifter maintained maximal strength, training volume, or sport performance.

Reading body-composition measurements

Body-composition methods answer different questions. DXA estimates bone, fat, and lean soft tissue from X-ray attenuation; it does not directly count muscle fibers or measure force. Hydration and glycogen can shift lean-mass estimates. MRI can map particular tissues more directly but is expensive and uncommon in large trials. Waist circumference and scale weight are practical but less specific.

For a lifter, the most useful evidence would pair a validated composition method with standardized strength testing, training logs, nutrition, and adequate follow-up. Retatrutide's current trials were designed primarily around obesity and metabolic outcomes, not preservation of a trained physique. That does not negate the trial benefit; it limits the answer to the question actually asked.

Comparison for gym-goers

Compound	Mechanism	Population studied	Outcome measured	What remains unproven for gym-goers
Retatrutide	GIP/GLP-1/glucagon receptor agonist	Adults with obesity; some studies in type 2 diabetes	Body weight, metabolic markers; DXA in substudies	Strength, muscle growth, safety or efficacy in lean cuts
Tesamorelin	GHRH analogue raising GH/IGF-1	Adults with HIV-associated lipodystrophy	Visceral adipose tissue	Spot reduction, general weight loss, bodybuilding benefit
Semaglutide	GLP-1 receptor agonist	Indication-specific obesity and diabetes populations	Weight and cardiometabolic outcomes	Guaranteed muscle preservation or athletic performance
Tirzepatide	GIP/GLP-1 receptor agonist	Indication-specific obesity and diabetes populations	Weight, metabolic outcomes; DXA substudy	Guaranteed muscle preservation or athletic performance

Where semaglutide and tirzepatide fit

Semaglutide is a GLP-1 receptor agonist; tirzepatide activates GIP and GLP-1 receptors. FDA-approved products have indication-specific prescribing information, established manufacturing, and clinical evidence. Their body-composition substudies show that fat accounts for more of the loss than lean tissue on average, but neither eliminates lean-mass loss or guarantees preserved strength.

Nothing in those studies supports combining semaglutide or tirzepatide with retatrutide or tesamorelin. Combining overlapping or growth-axis drugs raises questions not answered by studying each separately.

Reading future retatrutide headlines

Topline percentages should be read with the assigned dose, treatment duration, analysis population, discontinuation rules, and comparator. A press release may accurately summarize a primary endpoint while leaving body-composition methods, strength outcomes, subgroup uncertainty, and complete harms for later presentation. Regulatory review then considers the full application for a specific indication and product. None of those stages identifies an appropriate strategy for an individual lifter.

FAQ

Is retatrutide approved?

No. It remains investigational as of September 21, 2026. Phase 3 progress and sponsor announcements are not approval.

Is “GLP-3” a real receptor?

No. It is informal shorthand. Retatrutide acts at GIP, GLP-1, and glucagon receptors.

Did retatrutide preserve muscle?

Body-composition substudies suggest more fat than lean mass was lost. They do not show zero muscle loss, greater strength, or muscle growth.

Does tesamorelin spot-reduce belly fat?

Its approved evidence concerns visceral fat in HIV-associated lipodystrophy. That is not proof of cosmetic spot reduction.

Can these drugs be combined for a cut?

The cited evidence does not establish the safety or effectiveness of such combinations, and this article does not recommend them.